First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

Does first-line tislelizumab plus chemotherapy improve long-term outcomes compared with placebo plus chemotherapy in participants with recurrent or metastatic nasopharyngeal cancer?In this randomized clinical trial including 263 participants, tislelizumab plus chemotherapy demonstrated sustained progression-free survival benefit (median, 9.6 months vs 7.4 months) and clinically meaningful overall survival improvement (median, 45.3 months vs 31.8 months) compared with placebo plus chemotherapy after 3 years of follow-up, which is consistent with the interim analysis.These findings support tislelizumab plus chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal cancer, with the potential to provide sustained, long-term survival benefit.

Corresponding Authors: Wenfeng Fang, MD (fangwf@sysucc.org.cn), and Li Zhang, MD (zhangli@sysucc.org.cn), State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd E, Guangzhou, Guangdong 510060, China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.